<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961855</url>
  </required_header>
  <id_info>
    <org_study_id>CLIFE-01FV</org_study_id>
    <nct_id>NCT02961855</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of CLIFE1 Gel in Benign Anorectal Surgery</brief_title>
  <official_title>Double-blinded Multicenter Randomized Clinical Trial to Evaluate the Efficacy and Safety of CLIFE1 and CLIFE2 Gels in Benign Anorectal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Viladecans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Viladecans</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blinded multicenter randomized clinical trial to evaluate the efficacy and safety of
      CLIFE2 (lidocaine, referred as treatment A) respect CLIFE1 (lidocaine plus diclofenac,
      referred as treatment B) in benign anorectal surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      120 patients were randomly assigned to two groups (60 in each group). The study was conducted
      in two parallel groups, with 1:1 randomization stratified by type of surgery and centre.

      Treatment with CLIFE 1 and CLIFE 2 was applied from day 1 to day 6 post-surgery
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean level of pain, as assessed by visual analog scale (VAS)</measure>
    <time_frame>3 days post-surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean level of pain (VAS) at day 3 post-surgery</measure>
    <time_frame>6 days post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of pain (VAS), assessed by Andersen scale</measure>
    <time_frame>6 days post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief</measure>
    <time_frame>6 days post-surgery</time_frame>
    <description>Question about pain relief in comparison with the last application (scores from 0 to 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analgesics use</measure>
    <time_frame>6 days post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>6 days post-surgery</time_frame>
    <description>Satisfaction questionnaire about the efficacy of treatment (6 levels)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>demographic and clinical characteristics-1</measure>
    <time_frame>baseline</time_frame>
    <description>sex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>demographic and clinical characteristics-2</measure>
    <time_frame>baseline</time_frame>
    <description>age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety evaluation as assessed by recording fo adverse events</measure>
    <time_frame>6 days post-surgery</time_frame>
    <description>recording of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Fissure;Anal</condition>
  <condition>Fistula;Rectal</condition>
  <condition>Hemorrhoids</condition>
  <arm_group>
    <arm_group_label>Clife1 gel (lidocaine plus diclofenac)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clife1 gel (lidocaine plus diclofenac) Topical gel containing lidocaine (2%) plus diclofenac (0.5%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clife2 gel (lidocaine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clife2 gel (lidocaine) Topical gel containing lidocaine (2%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anesthesics plus antiinflammatory, CLIFE1</intervention_name>
    <description>anesthesics plus antiinflammatory, CLIFE1 topical gel containing lidocaine plus diclofenac anesthesics plus antiinflammatory</description>
    <arm_group_label>Clife1 gel (lidocaine plus diclofenac)</arm_group_label>
    <other_name>lidocaine plus diclofenac</other_name>
    <other_name>CLIFE1 topical gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>local anesthesics, CLIFE2</intervention_name>
    <description>local anesthesics, CLIFE2 topical gel containing lidocaine local anesthesics</description>
    <arm_group_label>Clife2 gel (lidocaine)</arm_group_label>
    <other_name>lidocaine</other_name>
    <other_name>CLEFE2 topical gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing benign anorectal surgery (out or inpatients), with the following
             diagnoses: anal fissure, fistula, hemorrhoids

          -  Use of subarachnoid anesthesia with lidocaine

        Exclusion Criteria:

          -  Allergy or Hypersensitivity to lidocaine or other local anesthesics.

          -  Patients not accepting subarachnoid anesthesia

          -  Patients with general anesthesia

          -  Hypersensitivity or contraindication to acetylsalicylic acid.

          -  History of gastrointestinal hemorrhage or perforation due to nonsteroidal
             anti-inflammatory drugs (NSAIDs) use

          -  Active or relapsing peptic ulcer/gastrointestinal hemorrhage

          -  Serious heart failure.

          -  Active Crohn disease

          -  Active ulcerative colitis

          -  Moderate or sever renal failure

          -  Severe liver disfunction

          -  Coagulation disorders requiring treatment with anticoagulant drugs

          -  Proctitis (due to autoimmune disease, foreign substances, sucally transmitted diseases

          -  Treatment with: Beta blockers, calcium channel blockers (verapamil and diltiazem),
             anti-arrhythmics (digoxin, amiodarone), ivabradine, lithium, steroids

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Viladecans</investigator_affiliation>
    <investigator_full_name>María José Linares Gil</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Hemorrhoids</mesh_term>
    <mesh_term>Rectal Fistula</mesh_term>
    <mesh_term>Fissure in Ano</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

